4‐HPR modulates gene expression in ovarian cells
Molly Brewer(UConn Health), Changping Zou(University of Arizona), Nathaniel D. Kirkpatrick, Robert C. Bast(The University of Texas MD Anderson Cancer Center), Jian Wang(Foshan Hospital of TCM), Nelly Auersperg(University of Central Florida), J. Taylor Wharton(The University of Texas MD Anderson Cancer Center), David M. Gershenson(The University of Texas MD Anderson Cancer Center), Kenneth D. Hatch(Banner - University Medical Center Tucson), Urs Utzinger(The University of Texas at Austin)
Cited by 9
Related Papers
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
|Endocrine Reviews|2001|999